Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
And Les could be teeing up something for release tomorrow.
(I think Kap was simply trying to inject some levity. Not everyone is a Kojac and picks up on all the references)
Chemo up to a point has shown to be potentially beneficial. In regards to L lots of discussion on the benefit of TMZ on this board over the past year.
With the prerequisite CT affirmation.
(The gang is all here and then some. Let's play nice)
Was only lacking CT affirmation.
Also agree. And also think (Imho) in regard to #2 process automation could be a huge wild card. Process automation lends itself better to NWBO's technology than say Kite or Juno's technology.
Agree, but DNDN is the perception at present.
I think (imho) the street street cannot perceive something that is old or a older technology as also being disruptive. In the streets eyes to be disruptive it also must be "new"
(And have market cap above $300mil)
I think (imho) Car-T being the relative new kid on the block (and the street does like what they perceive as disruptive technologies) has potential long term. Will need to be refined and might only be nich as costs will always be a challenge.
Someone should scale up some production capacity........oh wait
The Memphis (minus Blues and BBQ) of the U.K.
Thanks. I've stated NWBO needed to clear the NASDAQ issue before releasing investigation results. Looks like they intend to clear the BS lawsuits too. Considering the cloud of suspicion that has been hanging over the company from various sources probably good idea to clear the decks on everything. In this instance plaintiffs counsel is playing ball and is in position to make the smart call all while accruing some additional billable hours.
The end of the beginning not the beginning of the end.
DoingMyBest, As noted its been rather sporting on the board of late. I'm going to table the hypothetical discussion in favor of seeing what transpires over the next few weeks.
Enjoy......However with too much going on. I'll take the under (on days).
Hey Clay, Always good to have you in the house. You might want to stick around for longer than a cup of coffee (or tea as the case may be) this time.
Flirting with something and does not seem to be insolvency.
More balanced is less entertaining. ;)
Agree. And this needed to be resolved before the release of the investigation.
Reverse split 1/16.
doingmybest, would like to run a hypothetical by you and others (before it becomes moot). Are you keeping up with postings on the board?
Combo trials. Too much pointing to this the latest being Mav's posting of Novartis CEO comments. Besides Branko took L approval in 2018.
Will help tee-up my hypothetical at the expense of making it less of a hypothetical.
Doubling-down on posts today or is this the daily double?
I have a hypothetical I'll compile as time permits. Would like your take and doingmybest's take too as well as others from both sides of the NWBO coin (heads-up ex, Koman, AVII, ic) should be relatively NWBO neutral so no one will need to compromise their respective position.
I doubt anyone on the board is making the false presumption you are Captain Stubing.
Agree the legal short number should be down after today's action. Will be interested in the numbers on next report unless something else note worthy happens in the meantime.
Coming back from vacation (did not bump into Jim Cramer or Adam) and catching up on posts after being most decidedly unplugged for a week. Interesting stuff to say the least, thanks.
Agreed. And don't want to get too much into reading tea leaves, but will be interesting to see what has and/or will transpire and how things are aligned.
Expensive too. Would not be surprised if backers (some individually) of Cognate have more invested than Woodford. Not to add interest (no pun intended) to how they work out MFN with SEC.
Again. Been there done that.
Thanks for posting. As a BMY (BMS) share holder I have no argument with any of the points made by Mr. Jablow. Being published in NYT and with Mr. Jablow working for a health service provider I would hope it to have some impact at BMY (BMS). The Opdivo ads are self serving at minimum.......
They did a financing along the lines of what concerns China.....in regards to toxic financing as there are other concerns.
Thanks. In regards to combination trials I think most here including myself saw potential of CI with Direct due to tumor burden. I was somewhat surprised when Prins announced CI combo with L. And yes the trials with L will be a small university run study not a partnership in conjunction with BP as there is IMO a greater risk of an adverse side effect treating GBM with L/CI combo than treating solid tumors outside the cranium with a Direct/CI combo. That said they would be wise not to start the trials with L before trials with Direct are established lest any perceived mishap with L trials derail or delay Direct trials.
Longfellow95, Thanks for your insight and link. I own both BMY (BMS) and MRK. Been mulling this over for a while as I've been too busy to post much of any consequence. To paraphrase Sir Winston in regards to Direct-L-The FDA will do the right thing after exhausting the alternatives. I doubt if this is the intent or reason for the delay. But considering the autologous manufacturing complexity of Direct in comparison to say a relatively simple protein CI I would want to understand the efficacy of the easier to produce therapies before addressing the more complex to produce therapies. From this perspective, and as this space is evolving, the delay has likely helped the FDA in some respects. Would welcome your thoughts and I might ping DoingMyBest too for their perspective. TIA
Buff helping the Donald with taxes......which can be taxing
RK agree #3 not talked about enough, but think that is too changing. See my post 59286 with link to WP article. Within article is link to video from Parker Foundation with Dr. Ribas (UCLA) and Dr. James Allison (MD Anderson) talking about potential of combo therapies and interesting concepts such as stable disease "equilibrium with immune system"......From Dr. Allison no less. Listing to Dr. Allison there is little doubt he is from Texas......
Captain a new musical with bio-pharma-market implications which you might have some interst in recently opened in New York.
Thanks. And Woody's drinking issues* started to manifest itself in subsequent purchases of other suspect equities late that fall.
*Alleged